CompletedNot Applicable

18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis

United Kingdom53 participantsStarted 2019-10-22

Plain-language summary

18F-GP1 binds with high affinity to the glycoprotein IIb/IIIa receptors on activated platelets. 18F-GP1 PET-CT has recently demonstrated favourable safety, pharmacokinetic, biodistribution and diagnostic performance for the in vivo identification of venous and arterial thrombemboli.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ability to give informed consent * \>1 month post-surgical or transcatheter aortic valve replacement Exclusion Criteria: * Inability to give informed consent * Pregnancy or breastfeeding * Contraindications to iodinated contrast * Contraindications to anticoagulation * Use of anticoagulants during the post-operative period prior to screening * Extreme claustrophobia * Chronic kidney disease (with estimated glomerular filtration rate \<30 mL/min/1.73m2) * Metastatic malignancy * Inability to tolerate the supine position

What they're measuring

Prevalence of 18F-GP1 PET-CT bioprosthetic aortic valve uptake

Timeframe: 2 years

Intensity of 18F-GP1 PET-CT activity in bioprosthetic aortic valve thrombus

Timeframe: 2 years

Trial details

NCT IDNCT04073875

SponsorUniversity of Edinburgh

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-10-13

View on ClinicalTrials.gov More Thrombosis Cardiac trials